Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
作者信息
Pawar Ajinkya, Desai Rishi J, Liu Jun, Kim Erin, Kim Seoyoung C
机构信息
Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School Boston MA.
Division of Rheumatology, Immunology and Allergy Brigham and Women's Hospital and Harvard Medical School Boston MA.
出版信息
J Am Heart Assoc. 2021 Apr 6;10(7):e020045. doi: 10.1161/JAHA.120.020045. Epub 2021 Mar 25.
Abstract
摘要
相似文献
1
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.对开始使用非布司他与别嘌醇的老年痛风患者心血管风险的最新评估。
J Am Heart Assoc. 2021 Apr 6;10(7):e020045. doi: 10.1161/JAHA.120.020045. Epub 2021 Mar 25.
2
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.评估起始用非布司他与别嘌醇治疗老年痛风患者的心血管风险：基于人群的队列研究。
Circulation. 2018 Sep 11;138(11):1116-1126. doi: 10.1161/CIRCULATIONAHA.118.033992.
3
[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].痛风患者使用非布司他或别嘌醇：痛风合并心血管疾病患者中，非布司他和别嘌醇的心血管安全性（CARES研究）
Internist (Berl). 2020 May;61(5):530-532. doi: 10.1007/s00108-020-00766-4.
4
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.别嘌醇与非布司他治疗痛风患者的心血管风险比较：一项全国性队列研究。
Rheumatology (Oxford). 2019 Dec 1;58(12):2122-2129. doi: 10.1093/rheumatology/kez189.
5
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.风湿学新视角：痛风伴心血管疾病患者中非布司他和别嘌醇心血管安全性的意义——New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial 和相关的美国食品药品监督管理局公共安全警示。
Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583.
6
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
7
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.降尿酸治疗在痛风伴中重度慢性肾脏病患者中的成本比较。
J Manag Care Spec Pharm. 2016 Apr;22(4):326-36. doi: 10.18553/jmcp.2016.22.4.326.
8
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.比较非布司他和别嘌醇在真实世界中的心血管安全性：一项基于人群的队列研究。
Mayo Clin Proc. 2019 Jul;94(7):1147-1157. doi: 10.1016/j.mayocp.2019.03.001.
9
[Cardiovascular risk in gout - Role of allopurinol?].[痛风中的心血管风险 - 别嘌醇的作用？]
Ned Tijdschr Geneeskd. 2021 Apr 26;165:D5273.
10
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.非布司他对比别嘌醇用于痛风或无症状高尿酸血症患者的净临床获益：一项系统评价和荟萃分析。
Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1011-1022. doi: 10.1016/j.numecd.2019.06.016. Epub 2019 Jun 24.
引用本文的文献
1
Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout.基于群组的轨迹建模，用于评估美国商业保险的痛风成年患者对慢性降尿酸治疗的依从性。
J Manag Care Spec Pharm. 2025 Aug;31(8):795-807. doi: 10.18553/jmcp.2025.31.8.795.
2
Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches.高血压合并高尿酸血症的管理：纳米技术方法的引入。
Ann Med. 2024 Dec;56(1):2352022. doi: 10.1080/07853890.2024.2352022. Epub 2024 May 16.
3
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean.韩国痛风和高尿酸血症的流行病学及与治疗相关的问题
J Rheum Dis. 2023 Apr 1;30(2):88-98. doi: 10.4078/jrd.2022.0001. Epub 2023 Mar 17.
4
Review of Urate-Lowering Therapeutics: From the Past to the Future.尿酸降低疗法综述：从过去到未来
Front Pharmacol. 2022 Aug 23;13:925219. doi: 10.3389/fphar.2022.925219. eCollection 2022.
5
Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.黄嘌呤氧化酶抑制剂降低慢性肾脏病患者血清尿酸水平的疗效：一项系统评价和Meta分析
J Clin Med. 2022 Apr 27;11(9):2468. doi: 10.3390/jcm11092468.
本文引用的文献
1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.比较别嘌醇与非布司他治疗痛风患者的长期心血管安全性（FAST）：一项多中心、前瞻性、随机、开放标签、非劣效性试验。
Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9.
2
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.评估起始用非布司他与别嘌醇治疗老年痛风患者的心血管风险：基于人群的队列研究。
Circulation. 2018 Sep 11;138(11):1116-1126. doi: 10.1161/CIRCULATIONAHA.118.033992.
3
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
4
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.非布司他与别嘌醇及安慰剂对高尿酸血症和痛风患者降低血清尿酸的作用：一项为期28周的III期随机双盲平行组试验。
Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
5
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.非布司他与别嘌醇治疗高尿酸血症和痛风患者的比较。
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
Zotero 插件